AllianceBernstein’s Rapport Therapeutics RAPP Stock Holding History

AllianceBernstein’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.7M	Sell	693,384 -34,459	-5%	-$1.27M	0.01%	884
2026 Q1	$22.1M	Sell	727,843 -60,568	-8%	-$1.7M	0.01%	873
2025 Q4	$23.9M	Sell	788,411 -67,209	-8%	-$1.86M	0.01%	874
2025 Q3	$25.4M	Sell	855,620 -299,068	-26%	-$5.33M	0.01%	836
2025 Q2	$13.1M	Buy	1,154,688 +45,063	+4%	+$478K	﹤0.01%	1063
2025 Q1	$11.1M	Buy	1,109,625 +11,210	+1%	+$146K	﹤0.01%	1118
2024 Q4	$19.5M	Buy	1,098,415 +9,494	+0.9%	+$210K	0.01%	903
2024 Q3	$22.3M	Sell	1,088,921 -1,937	-0.2%	-$41.6K	0.01%	870
2024 Q2	$25.4M	Buy	+1,090,858	New	+$25.3M	0.01%	804

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

AllianceBernstein's RAPP Position: Q2 2026 in Review

AllianceBernstein reduced its Rapport Therapeutics (RAPP) stake by 4.7% in Q2 2026, selling an estimated $1.27M and leaving 693,384 shares worth $21.7M. The position accounts for 0.01% of the portfolio, ranked #884.

AllianceBernstein first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. The position peaked at $25.4M in Q3 2025. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

AllianceBernstein held 693,384 shares of Rapport Therapeutics worth $21.7M as of Q2 2026.
AllianceBernstein sold 34,459 Rapport Therapeutics shares in Q2 2026, an estimated $1.27M.
Rapport Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #884 holding.
AllianceBernstein first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
AllianceBernstein's Rapport Therapeutics position peaked at $25.4M in Q3 2025.
161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.